|1.||Naber, Dieter: 3 articles (01/2015 - 03/2011)|
|2.||Pudas, Hanna: 3 articles (09/2013 - 01/2012)|
|3.||Schöttle, Daniel: 2 articles (01/2015 - 11/2013)|
|4.||Piwko, Charles: 2 articles (09/2013 - 04/2013)|
|5.||Zilbershtein, Roman: 2 articles (09/2013 - 04/2013)|
|6.||Einarson, Thomas R: 2 articles (09/2013 - 04/2013)|
|7.||Vicente, Colin: 2 articles (09/2013 - 04/2013)|
|8.||Hemels, Michiel E H: 2 articles (09/2013 - 04/2013)|
|9.||Sommerfeld, Karina: 1 article (09/2015)|
|10.||Zielińska-Psuja, Barbara: 1 article (09/2015)|
|1.||Schizophrenia (Dementia Praecox)
01/01/2009 - "Two double-blind randomised clinical trials of olanzapine pamoate were conducted and demonstrate efficacy for both the acute treatment of schizophrenia and for the maintenance of antipsychotic response. "
01/01/2010 - "The most significant studies published to date, on the use of olanzapine pamoate in schizophrenia, are reviewed in this article. "
01/01/2008 - "D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia."
10/01/2014 - "An evaluation of the use of olanzapine pamoate depot injection in seriously violent men with schizophrenia in a UK high-security hospital."
01/01/2014 - "A 42-year-old patient with a schizophrenic disorder lost consciousness 30 min after administration of olanzapine pamoate. "
01/01/2015 - "LAIs show a similar safety profile to oral formulations of the relevant drug, with the exception of olanzapine pamoate, which can lead to rare cases of post-injection delirium/sedation syndrome (PDSS). "
01/01/2015 - "Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management."
01/01/2014 - "[Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: a new syndrome in emergency psychiatry]."
03/01/2013 - "Postinjection delirium/sedation syndrome is a potentially serious adverse event that has been shown to be associated with one currently available LAI antipsychotic, olanzapine pamoate. "
03/01/2013 - "However, research into the safety and tolerability of these LAIs, with particular regard to the development of postinjection delirium/sedation syndrome (PDSS), is limited and has been focused mainly on olanzapine pamoate. "
|3.||Psychotic Disorders (Schizoaffective Disorder)
|5.||Drug Toxicity (Drug Safety)
11/01/2013 - "Drug safety evaluation of olanzapine pamoate."
|2.||Risperidone (Risperdal Consta)
|4.||Antipsychotic Agents (Antipsychotics)
|8.||fluphenazine depot (modecate)